68 results about "Propranolol" patented technology

It has been discovered that the stimulation of beta-adrenergic receptors, which activate cAMP formation, give rise to increased APP and GFAP synthesis in astrocytes. Hence, the in vitro or in vivo exposure of neuronal cells to certain compositions comprising beta-adrenergic receptor ligands or agonists, including, e.g., norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. These increases are blocked by beta-adrenergic receptor antagonists, such as propranolol. The in vitro or in vivo treatment of these cells with 8Br-cAMP, prostaglandin E2 (PG E2), forskolin, and nicotine ditartrate also increased APP synthesis, including an increase in mRNA and holoprotein levels, as well as an increase in the expression of glial fibrillary acidic protein (GFAP). Compositions and methods are disclosed of regulating APP overexpression and mediating reactive astrogliosis through cAMP signaling or the activation of beta-adrenergic receptors. It has further been found that the increase in APP synthesis caused by 8Br-cAMP, PG E2, or forskolin is inhibited by immunosuppressants, immunophilin ligands, or anti-inflammatory agents, such as cyclosporin A, and FK-506 (tacrolimus), as well as ion-channel modulators, including ion chelating agents such as EGTA, or calcium / calmodulin kinase inhibitors, such as KN93. The present invention has broad implications in the alleviation, treatment, or prevention of neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.

A unit dosage form, such as a capsule or the like for delivering drugs into the body in a circadian release fashion, is comprising of one or more populations of propranolol-containing particles (beads, pellets, granules, etc.). Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release cardiovascular drug delivery system is designed to provide a plasma concentration-time profile, which varies according to physiological need during the day, i.e., mimicking the circadian rhythm and severity / manifestation of a cardiovascular disease, predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro / in vivo correlations.

The invention provides a preparation method of a graphene oxide / attapulgite magnetic composite material for removing propranolol in a water body. Graphene oxide is prepared by utilizing an improved Hummers method, and then a composite material is prepared by mixing and reaction with attapulgite. The prepared composite material is taken as an adsorbent, propranolol is taken as an adsorption object,and experimental results show that the composite material has efficient adsorption and removal effects; compared with single graphene oxide, the composite material is low in production cost, and theused attapulgite is cheap and easy to obtain. The composite material applied to treat the propranolol in the water body has the advantages of being low in price, simple to operate, high in adsorptionrate, environmentally friendly, high in stability, easy to separate and the like, and has certain practical value in industrialization. The graphene oxide / attapulgite magnetic composite material has certain practical value as an adsorbent for treating cardiovascular drugs in sewage and provides a brand-new water treatment idea in the field of water treatment.

The invention discloses a delayed-release preparation of propranolol for treating cardiovascular diseases such as abnormal heart rate, angina, myocardial infarction and the like or a salt thereof. The aim of the invention is to provide a drug preparation which meets the intentions of chrono-pharmacology and chrono-therapeutics and has the delayed and impulse drug-release effects and a method for preparing the same. The delayed-release preparation comprises: a tablet core containing the active component propranolol with effective treating dose or the salt thereof and other auxiliary materials and one or two coating layers which are coated in a coating pan by the rollover method or coated by the fluidization coating method or dry pressing coating method. The composition and the thickness ofthe coating layers decide the time lag of releasing the drug.